NURR1 plays a key role in the maintenance of the dopaminergic system of the brain. Mutations in this gene have been associated with disorders related to dopaminergic dysfunction, including Parkinson's disease, schizophrenia, and manic depression. Misregulation of this gene may be associated with rheumatoid arthritis. Four transcript variants encoding four distinct isoforms have been identified for this gene. Additional alternate splice variants may exist, but their full-length nature has not been determined.
This protein is thought to be critical to development of the dopamine phenotype in the midbrain, as mice without NURR1 are lacking expression of this phenotype. This is further confirmed by studies showing that when forcing NURR1 expression in naïve precursor cells, there is complete dopamine phenotype gene expression. 
While NURR1 is a key protein, there are other factors required as research shows that solely expressing NURR1 fails to stimulate this phenotypic gene expression. One of these suggested factors is winged-helix transcription factor 2 (Foxa2). Studies have found these two factors to be within the same region of developing dopaminergic neurons, both of these factors were present in order to have expression for the dopamine phenotype. 
Research has been conducted on Nurr1’s role in inflammation, and may provide important information in treating disorders caused by dopaminergic neuron disease. Inflammation in the CNS can result from activated microglia (macrophage analogs for the central nervous system) and other pro-inflammatory factors, such as bacterial lipopolysaccharide (LPS). LPS binds to toll-like receptors (TLR), which induces inflammatory gene expression by promoting signal-dependent transcription factors. To determine which cells are dopaminergic, experiments measured the enzyme tyrosine hydroxylase (TH), which is needed for dopamine synthesis. It has been shown that Nurr1 protects dopaminergic neurons from LPS-induced inflammation, by reducing inflammatory gene expression in microglia and astrocytes. When a short hairpin for Nurr1 was expressed in microglia and astrocytes, these cells produced inflammatory mediators, such as TNFa, NO synthase and IL-1β, supporting the conclusion that reduced Nurr1 promotes inflammation and leads to cell death of dopaminergic neurons. Nurr1 interacts with the transcription factor complex NF-κB-p65 on the inflammatory gene promoters. However, Nurr1 is dependent on other factors to be able to participate in these interactions. Nurr1 needs to be sumoylated and its co-regulating factor, glycogen synthase kinase 3, needs to be phosphorylated for these interactions to occur. Sumolyated Nurr1 recruits CoREST, a complex made of several proteins that assembles chromatin-modifying enzymes. The Nurr1/CoREST complex inhibits transcription of inflammatory genes.
One investigation conducted research on the structure and found that Nurr1 does not contain a ligand-binding cavity but a patch filled with hydrophobic side chains. Non-polar amino acid residues of Nurr1’s co-regulators, SMRT and NCoR, bind to this hydrophobic patch. Analysis of tertiary structure has shown that the binding surface of the ligand-binding domain is located on the grooves of the 11th and 12th alpha helices. This study also found essential structural components of this hydrophobic patch, to be the three amino acids residues, F574, F592, L593; mutation of any these three inhibits LBD activity.
Nurr1 induces tyrosine hydroxylase (TH) expression, which eventually leads to differentiation into dopaminergic neurons. Nurr1 has been demonstrated to induce differentiation in CNS precursor cells in vitro but they require additional factors to reach full maturity and dopaminergic differentiation. Therefore, Nurr1 modulation may be promising for generation of dopaminergic neurons for Parkinson’s disease research, yet implantation of these induced cells as therapy treatments, has had limited results.
Studies have shown that heterozygous knockout mice for the NURR1 gene demonstrate reduced dopamine release. Initially this was compensated for by a decrease in the rate of dopamine reuptake; however, over time this reuptake could not make up for the reduced amount of dopamine being released. Coupled with the loss of dopamine receptor neurons, this can result in the onset of symptoms for Parkinson’s Disease. 
^ abYi, Sang-Hoon; He, Xi-Biao; Rhee, Yong-Hee; Park, Chang-Hwan; Takizawa, Takumi; Nakashima, Kinichi; Lee, Sang-Hun (15 February 2014). "Foxa2 Acts as a Co-activator Potentiating Expression of the Nurr1-induced DA Phenotype via Epigenetic Regulation.". Development.|access-date= requires |url= (help)
^Codina A, Benoit G, Gooch JT, Neuhaus D, Perlmann T, Schwabe JW (Dec 2004). "Identification of a novel co-regulator interaction surface on the ligand binding domain of Nurr1 using NMR footprinting". The Journal of Biological Chemistry. 279 (51): 53338–45. PMID15456745. doi:10.1074/jbc.M409096200.
^Kim JY, Koh HC, Lee JY, Chang MY, Kim YC, Chung HY, Son H, Lee YS, Studer L, McKay R, Lee SH (Jun 2003). "Dopaminergic neuronal differentiation from rat embryonic neural precursors by Nurr1 overexpression". Journal of Neurochemistry. 85 (6): 1443–54. PMID12787064. doi:10.1046/j.1471-4159.2003.01780.x.
^Zhang, Lifen; Le, Weidong; Xie, Wenjie; Dani, John A (2012). "Age-related Changes in Dopamine Signaling in Nurr1 Deficient Mice as a Model of Parkinson's Disease". Neurobiology of Aging. PMID21531044.|access-date= requires |url= (help)
^Jacobs FM, van Erp S, van der Linden AJ, von Oerthel L, Burbach JP, Smidt MP (February 2009). "Pitx3 potentiates Nurr1 in dopamine neuron terminal differentiation through release of SMRT-mediated repression". Development. 136 (4): 531–40. PMID19144721. doi:10.1242/dev.029769.
^ abPerlmann T, Jansson L (Apr 1995). "A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and NURR1". Genes & Development. 9 (7): 769–82. PMID7705655. doi:10.1101/gad.9.7.769.
Wedler B, Wüstenberg PW, Naumann G (Jul 1975). "[Treatment of hypertonus in diabetes mellitus]". Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete. 30 (13): 437–42. PMID4929.
Perlmann T, Jansson L (Apr 1995). "A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and NURR1". Genes & Development. 9 (7): 769–82. PMID7705655. doi:10.1101/gad.9.7.769.
Forman BM, Umesono K, Chen J, Evans RM (May 1995). "Unique response pathways are established by allosteric interactions among nuclear hormone receptors". Cell. 81 (4): 541–50. PMID7758108. doi:10.1016/0092-8674(95)90075-6.
Mages HW, Rilke O, Bravo R, Senger G, Kroczek RA (Nov 1994). "NOT, a human immediate-early response gene closely related to the steroid/thyroid hormone receptor NAK1/TR3". Molecular Endocrinology. 8 (11): 1583–91. PMID7877627. doi:10.1210/me.8.11.1583.
Maruyama K, Sugano S (Jan 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1-2): 171–4. PMID8125298. doi:10.1016/0378-1119(94)90802-8.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (Oct 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1-2): 149–56. PMID9373149. doi:10.1016/S0378-1119(97)00411-3.
Ichinose H, Ohye T, Suzuki T, Sumi-Ichinose C, Nomura T, Hagino Y, Nagatsu T (Apr 1999). "Molecular cloning of the human Nurr1 gene: characterization of the human gene and cDNAs". Gene. 230 (2): 233–9. PMID10216262. doi:10.1016/S0378-1119(99)00065-7.
Chen YH, Tsai MT, Shaw CK, Chen CH (Dec 2001). "Mutation analysis of the human NR4A2 gene, an essential gene for midbrain dopaminergic neurogenesis, in schizophrenic patients". American Journal of Medical Genetics. 105 (8): 753–7. PMID11803525. doi:10.1002/ajmg.10036.
Ishiguro H, Okubo Y, Ohtsuki T, Yamakawa-Kobayashi K, Arinami T (Jan 2002). "Mutation analysis of the retinoid X receptor beta, nuclear-related receptor 1, and peroxisome proliferator-activated receptor alpha genes in schizophrenia and alcohol dependence: possible haplotype association of nuclear-related receptor 1 gene to alcohol dependence". American Journal of Medical Genetics. 114 (1): 15–23. PMID11840500. doi:10.1002/ajmg.1620.
McEvoy AN, Murphy EA, Ponnio T, Conneely OM, Bresnihan B, FitzGerald O, Murphy EP (Mar 2002). "Activation of nuclear orphan receptor NURR1 transcription by NF-kappa B and cyclic adenosine 5'-monophosphate response element-binding protein in rheumatoid arthritis synovial tissue". Journal of Immunology. 168 (6): 2979–87. PMID11884470. doi:10.4049/jimmunol.168.6.2979.
Xu PY, Liang R, Jankovic J, Hunter C, Zeng YX, Ashizawa T, Lai D, Le WD (Mar 2002). "Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease". Neurology. 58 (6): 881–4. PMID11914402. doi:10.1212/wnl.58.6.881.
Le WD, Xu P, Jankovic J, Jiang H, Appel SH, Smith RG, Vassilatis DK (Jan 2003). "Mutations in NR4A2 associated with familial Parkinson disease". Nature Genetics. 33 (1): 85–9. PMID12496759. doi:10.1038/ng1066.
Satoh J, Kuroda Y (Dec 2002). "The constitutive and inducible expression of Nurr1, a key regulator of dopaminergic neuronal differentiation, in human neural and non-neural cell lines". Neuropathology. 22 (4): 219–32. PMID12564761. doi:10.1046/j.1440-1789.2002.00460.x.
Iwayama-Shigeno Y, Yamada K, Toyota T, Shimizu H, Hattori E, Yoshitsugu K, Fujisawa T, Yoshida Y, Kobayashi T, Toru M, Kurumaji A, Detera-Wadleigh S, Yoshikawa T (Apr 2003). "Distribution of haplotypes derived from three common variants of the NR4A2 gene in Japanese patients with schizophrenia". American Journal of Medical Genetics Part B. 118B (1): 20–4. PMID12627459. doi:10.1002/ajmg.b.10053.
Kim KS, Kim CH, Hwang DY, Seo H, Chung S, Hong SJ, Lim JK, Anderson T, Isacson O (May 2003). "Orphan nuclear receptor Nurr1 directly transactivates the promoter activity of the tyrosine hydroxylase gene in a cell-specific manner". Journal of Neurochemistry. 85 (3): 622–34. PMID12694388. doi:10.1046/j.1471-4159.2003.01671.x.